ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 230 for:    Recruiting, Not yet recruiting, Available Studies | "Hodgkin Disease"

Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. (LHGALOP2017)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03500133
Recruitment Status : Recruiting
First Posted : April 17, 2018
Last Update Posted : April 23, 2018
Sponsor:
Collaborator:
Hospital Pereyra Rosell, Montevideo, Uruguay
Information provided by (Responsible Party):
Guillermo Chantada, Hospital JP Garrahan

Brief Summary:

This trial proposes a therapy for pediatric Hodgkin lymphoma with the objective of achieving high levels of long lasting complete remission with less risk of late effects.

Patients of both genders, between 2 and 18 years, with newly diagnosed classical Hodgkin lymphoma are admitted.

Initial staging provides stratification in three groups: low, intermediate and high risk. An initial set of two chemotherapy courses is administered to all cases after which a new disease assessment is performed. According to disease response a final therapy group is assigned. Rapid early responders benefit from less chemotherapy. At the end of chemotherapy, radiotherapy is delivered only to patients who do not achieve a complete response. Thus therapy is tailored to initial extension and disease responsiveness. Complete responders at the end of chemotherapy do not receive radiotherapy. Those who are in partial remission receive low dose (30Gy) involved node radiotherapy. Stable or progressive disease at any moment is assumed as a trial failure and new therapeutic strategies are offered to patients off protocol.

Chemotherapy is based upon regimes with well known effectiveness in Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide, methyl prednisolone, citarabine and cisplatin). The schedules are delivered with low cumulative drug doses and avoiding the use of toxic alkylating agents. Risks of secondary leukemia and infertility are thus minimized. Doxorubicin and bleomycin do not achieve cumulative doses that may expose to significant risk of heart or lung damage. Radiotherapy reduction avoids late radiation sequels.

This clinical study proposes a therapeutic approach based on chemotherapy that do not sum up high cumulative toxic doses. Therapy is tailored according to initial risk assessment and disease responsiveness. Those who achieve a complete response to chemotherapy do not receive additional radiotherapy, thus avoiding further late effects.


Condition or disease Intervention/treatment Phase
Pediatric Hodgkin's Disease Radiation: No radiotherapy if CR at the end of chemotherapy. Drug: Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered. Drug: Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered. Radiation: IN 30Gy RT in case of PR at the end of chemotherapy Drug: Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered. Drug: Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD. Drug: High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD. Drug: High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD. Drug: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered. Phase 4

Detailed Description:

This trial proposes a therapy for pediatric Hodgkin lymphoma with the objective of achieving high levels of long lasting complete remission with less risk of late effects.

Patients of both genders, between 2 and 18 years, with newly diagnosed classical Hodgkin lymphoma are admitted. An open surgical biopsy with histopatological diagnosis is preferred.

Initial staging provides stratification in three groups: low, intermediate and high risk. An initial set of two chemotherapy courses is administered to all cases after which an early disease response assessment is performed. According to disease response a final therapy group is assigned (7 arms).

Imaging with PET-CT and Deauville Score is preferred for initial and further disease assessment. Complete response is defined by volume reduction and metabolic remission. In case PET-CT is not available, CT and ultrasound with volume reduction standards to assess response may be used.

Rapid early responders who achieve complete remission (CR) benefit from less chemotherapy. Those who are in partial remission at the end of chemotherapy (late disease assessment) receive low dose (30Gy) involved node radiotherapy. At the end of chemotherapy, radiotherapy is delivered only to patients who do not achieve a CR. Thus, therapy is tailored according to initial extension and disease responsiveness. Complete responders at the end of chemotherapy do not receive radiotherapy. To avoid radiotherapy in the majority of cases constitutes a principal goal of this trial. Stable or progressive disease at any moment is assumed as a trial failure and new therapeutic strategies are offered to these patients off protocol.

Chemotherapy is based upon regimes with well known effectiveness in Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide, methyl prednisolone, citarabine and cisplatin).

Low risk arms (Arms A, B and B2) receive no more than 4 cycles of ABVD. Intermediate risk Arm C, 5 cycles of ABVD and Arm D 4 cycles of ABVD and 2 courses of ESHAP. High risk Arm E receives 3 cycles of ABVD and 3 Cycles of ESHAP, Arm F receives 4 courses of ABVD and 4 courses of ESHAP. The schedules are delivered projecting low cumulative drug doses and avoiding the use of toxic alkylating agents. Risks of secondary leukemia and infertility are thus minimized. Doxorubicin and bleomycin do not achieve cumulative doses that may expose to significant risk of heart or lung damage. Radiotherapy reduction avoids late radiation sequels.

Cardiac, lung , thyroid and any other toxic effects are prospectively assessed at onset and regularly during and after therapy.

The main event-free and overall survival proportions end points will be analyzed annually during the following 10 years after the last patient registration.

This clinical study proposes a therapeutic approach based on chemotherapy that do not sum up high cumulative toxic doses. Therapy is tailored according to initial risk assessment and disease responsiveness. Those who achieve a complete response after chemotherapy do not receive additional radiotherapy, thus avoiding further late effects.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Initial disease risk assignment defines three arms: low, intermediate and high risk. After early disease response assessment 7 Arms are defined, treated with more intense chemotherapy according to initial risk and therapy response. Finally radiotherapy is delivered only to patients who do not achieve complete remission after chemotherapy at late disease response assessment.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy.
Actual Study Start Date : October 6, 2017
Estimated Primary Completion Date : October 31, 2027
Estimated Study Completion Date : October 31, 2032


Arm Intervention/treatment
Experimental: Group A

Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.

No radiotherapy if CR at the end of chemotherapy.

Radiation: No radiotherapy if CR at the end of chemotherapy.
Adapted chemotherapy without radiotherapy

Drug: Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.

Experimental: Group B

Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.

No radiotherapy if CR at the end of chemotherapy

Radiation: No radiotherapy if CR at the end of chemotherapy.
Adapted chemotherapy without radiotherapy

Drug: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.

Experimental: Group B2

Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.

No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy

Radiation: No radiotherapy if CR at the end of chemotherapy.
Adapted chemotherapy without radiotherapy

Drug: Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.
Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.

Radiation: IN 30Gy RT in case of PR at the end of chemotherapy
Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT

Experimental: Group C

Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.

No radiotherapy if CR at the end of chemotherapy.

Radiation: No radiotherapy if CR at the end of chemotherapy.
Adapted chemotherapy without radiotherapy

Drug: Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.

Experimental: Group D

Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.

No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy

Radiation: No radiotherapy if CR at the end of chemotherapy.
Adapted chemotherapy without radiotherapy

Radiation: IN 30Gy RT in case of PR at the end of chemotherapy
Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT

Drug: Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.

Experimental: Group E

High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.

No radiotherapy if CR at the end of chemotherapy

Radiation: No radiotherapy if CR at the end of chemotherapy.
Adapted chemotherapy without radiotherapy

Drug: High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.

Experimental: Group F

High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.

No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy

Radiation: No radiotherapy if CR at the end of chemotherapy.
Adapted chemotherapy without radiotherapy

Radiation: IN 30Gy RT in case of PR at the end of chemotherapy
Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT

Drug: High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.




Primary Outcome Measures :
  1. Event-free Survival [ Time Frame: 3-10 years ]
    Event free survival probability (event= relapse or death)

  2. Overall Survival [ Time Frame: 3-10 years ]
    Overall survival probability (event= death)


Secondary Outcome Measures :
  1. Acute, chronic or late toxic events [ Time Frame: 0-10 years ]
    Number of patientsexperiencing treatment-related adverse effects and mortality according to CTCAE v4.0



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histopathological diagnosis of classical Hodgkin lymphoma.
  • Normal renal, hepatic, pulmonary and metabolic function standards.
  • Informed consent signed by patient and/or legal caretakers.

Exclusion Criteria:

  • Lymphocyte predominant nodular Hodgkin lymphoma
  • Any form of immunodeficiency before diagnosis. (primary immunodeficiencies, trasplant recipients or immunosuppressive therapies of any kind including corticoid therapies during 28 days before diagnosis).
  • Pregnancy and breastfeeding period.
  • Sexually active female patients who do not accept an effective contraceptive method during therapy.
  • Positive HIV serology.
  • Penfigus or hepatic ductopenia.
  • Hodgkin lymphoma as a secondary malignant disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03500133


Contacts
Contact: Pedro A Zubizarreta, MD +541131207433 pedro.zubizarreta@hotmail.com
Contact: Elizabeth M Alfaro, MD +541159763263 elizabeth2006_alfaro@yahoo.com.ar

Locations
Argentina
Hospital JP Garrahan Recruiting
Buenos Aires, CF, Argentina, C1245AAL
Contact: Carolina Cernadas, MD    541141226335    coordinacioninvestigacion@garrahan.gov.ar   
Contact: Guillermo L Chantada, MD, PhD    541141226000    gchantada@yahoo.com   
Sub-Investigator: Elizabeth Alfaro, MD         
Sub-Investigator: Myriam Guitter, MD         
Sub-Investigator: Cristian Sanchez La Rosa, MD         
Sub-Investigator: María Sara Felice, MD         
Sponsors and Collaborators
Hospital JP Garrahan
Hospital Pereyra Rosell, Montevideo, Uruguay

Publications:
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68.

Responsible Party: Guillermo Chantada, MD, Hospital JP Garrahan
ClinicalTrials.gov Identifier: NCT03500133     History of Changes
Other Study ID Numbers: 991 Hodgkin Lymphoma GALOP2017
First Posted: April 17, 2018    Key Record Dates
Last Update Posted: April 23, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Guillermo Chantada, Hospital JP Garrahan:
Pediatric Hodgkin Lymphoma, therapy, reduced radiotherapy

Additional relevant MeSH terms:
Lymphoma
Hodgkin Disease
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases